NCT06568367 - Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | Biotech Hunter

Enrollment

520

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Excessive SleepinessShift-work Disorder

Interventions

DRUG

Solriamfetol 150 mg

Solriamfetol tablets, taken once daily

DRUG

Solriamfetol 300 mg

Solriamfetol tablets, taken once daily

DRUG

Placebo

Placebo tablets, taken once daily

Trial Locations (25)

19610

RECRUITING

Clinical Research Site, Wyomissing

28037

RECRUITING

Clinical Research Site, Denver

28078

RECRUITING

Clinical Research Site, Huntersville

29201

RECRUITING

Clinical Research Site, Columbia

29425

RECRUITING

Clinical Research Site, Charleston

30238

RECRUITING

Clinical Research Site, Atlanta

30281

RECRUITING

Clinical Research Site, Stockbridge

33016

RECRUITING

Clinical Research Site, Hialeah

RECRUITING

Clinical Research Site, Miami Lakes

33144

RECRUITING

Clinical Research Site, Miami

33176

RECRUITING

Clinical Research Site, Miami

33186

RECRUITING

Clinical Research Site, Miami

45212

RECRUITING

Clinical Research Site, Cincinnati

45245

RECRUITING

Clinical Research Site, Cincinnati

48076

RECRUITING

Clinical Research Site, Lathrup Village

48377

RECRUITING

Clinical Research Site, Novi

63017

RECRUITING

Clinical Research Site, Chesterfield

63123

RECRUITING

Clinical Research Site, St Louis

72211

RECRUITING

Clinical Research Site, Little Rock

78229

RECRUITING

Clinical Research Site, San Antonio

80918

RECRUITING

Clinical Research Site, Colorado Springs

90703

RECRUITING

Clinical Research Site, Cerritos

90805

RECRUITING

Clinical Research Site, Long Beach

91910

RECRUITING

Clinical Research Site, Chula Vista

92705

RECRUITING

Clinical Research Site, Santa Ana